Jyong Biotech is a Cayman holding company whose Taiwan laboratory spent two decades building plant-derived urology candidates, listed those shares on Nasdaq last summer, and then watched the public story split in two. On one side sits a completed Taiwan Phase Two prevention study in more than seven hundred high-risk men that cut prostate-cancer incidence versus placebo and added a lipid signal the company now tries to sell as a second franchise. On the other side sits a year-end cash balance that barely covers a few months of the current burn, a final mainland judgment larger than the entire initial offering, and a related-party loan that moved most of the new public capital off the operating balance sheet. The equity still trades as if a global botanical franchise is one license signature away. The audited accounts read as if the franchise is an option the company can no longer fund on its own.
The offering priced ordinary shares at seven and a half apiece and raised about $20 million before fees. Those shares now change hands near $2.06. The collapse has taken the capitalization to roughly $157 million. Year-end cash is about $1.2 million. Product revenue remains zero across the last three audited years. The latest full-year net loss was $4.7 million on research spending that would not fund a single United States registrational trial. The auditor attached substantial-doubt language, and management recorded a material weakness in financial reporting. The market is therefore not capitalizing a going commercial business. It is capitalizing the chance that a partner writes a check large enough to restart Botreso after the first-source active ingredient disappeared and to carry the prevention candidate into a multinational Phase Three the cash account cannot touch.
What happens next is not another press-cycle recitation of botanical science. The next twelve months resolve whether a binding license replaces the non-binding Korean letter and the Vietnamese memorandum, whether the Food and Drug Administration accepts a second-source comparability package that still is not complete, and whether the Taizhou judgment is settled before enforcement against Taiwan, Hong Kong, and Cayman assets becomes the residual claim. If a funded partner appears, the Phase Two prevention print can support a real development budget. If the related-party receivable stays outstanding and the court claim is collected, the public float is left holding an unfunded option. That is the investment debate.